Clinical Trials Logo

Citation(s)

  •   Arthur E
    Frankel, Jung H. Woo, Jeremy P. Mauldin, Francine M. Foss, Madeleine Duvic, David M. Neville Jr. An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas—CTCL. Post
  •   Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM
    Resimmune, an anti-CD3e recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015
  •   Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, Neville DM, Woo JH
    Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets. 2009 Feb;10(2):104-9. Review.
  •   Frankel, Arthur E
    Anti-CD3 immunotoxin to induce remissions in cutaneous T-cell lymphoma patients. Poster session presented at: 2012 American Society of Clinical Oncology (ASCO). Oral Abstract Session, Developmental Therapeutics - Clinical Pharmacology a

A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma

Details for clinical trial NCT00611208